Karyopharm, the parent of cell therapy maker Gamida Cell, is heading toward a bankruptcy process and a court-supervised auction, with the bidder structure expected to determine who acquires the commercial-stage blood cancer biotech. The update comes after Karyopharm cut a forbearance deal aimed at delaying debt payments. The report frames the auction as a narrowing of options for stakeholders while the company pursues a sale route rather than continued standalone operations. The broader context is pressure on cash-constrained biopharma firms following clinical and financing challenges. For investors tracking restructuring risk, the case highlights how debt and liquidity constraints can translate into asset sales even for companies with late-stage product franchises.